Ophthalmic preparation and preparation method and application thereof

An ophthalmic preparation and content technology, applied in the field of protein engineering, can solve the problem of unsatisfactory transthyretin effect and achieve the effect of improving the therapeutic effect

Active Publication Date: 2020-12-08
易舟(上海)生物医药有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Aiming at the shortcomings in the prior art that the effect of transthyretin (TTR) alone in the treatment of eye dise

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic preparation and preparation method and application thereof
  • Ophthalmic preparation and preparation method and application thereof
  • Ophthalmic preparation and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Embodiment 1 Recombinant preparation of human transthyretin (TTR)

[0067] (1) Construction of the recombinant plasmid pETx-rhaPBAD-ttr: transform and restructure the pET-21a plasmid (purchased from the ATCC China Culture Collection Center) (the difference in sequence between the restructured plasmid and the original pET-21a plasmid is About 75%, the specific sequence is shown in SEQ ID NO: 4), and the rhaPBAD promoter (Rhamna Tang inducible) is used to replace the T7 promoter, and the human TTR optimized nucleic acid sequence is connected at the same time (as shown in SEQ ID NO: 2 , the amino acid sequence of TTR is shown in SEQ ID NO:1), and the overall nucleic acid sequence of the resulting plasmid is shown in SEQ ID NO:3. After sequencing verification (the sequencing company is Nanjing GenScript Biotechnology Co., Ltd.), the construction was successful.

[0068] (2) Expression and purification of recombinant human TTR: transform the pETx-rhaPBAD-ttr plasmid constru...

Embodiment 2

[0071] Example 2 Computer Simulation of the Binding Form of TTR and Each Ligand Molecule

[0072] Refer to the static co-crystal model (PDF: 3CFQ) of TTR dimer and diclofenac in the PDB database, such as Figure 4A shown. Figure 4AIn , the protein structure is a TTR dimer, and the diclofenac ligand molecule is indicated by an arrow, and one molecule of TTR dimer can bind two molecules of diclofenac. Figure 4B The interaction of diclofenac with TTR amino acid residues is shown in .

[0073] Molecular simulation by Discovery studio software found that vitamin A1 (retinol) can stably bind to the hydrophobic channel of TTR polymer. Figure 5A The protein structure shown in is a TTR dimer, the vitamin A1 ligand molecule is indicated by an arrow, and one molecule of TTR dimer can bind one molecule of vitamin A1. Figure 5B The interaction of vitamin A1 with TTR amino acid residues is shown in .

[0074] Molecular simulation by Discovery studio software found that vitamin A2 (3...

Embodiment 3

[0077] Example 3 Determination of dynamic specific binding parameters between TTR and each potential ligand molecule

[0078] Use nano ITC (TA) to measure the affinity binding equilibrium dissociation constant K of TTR and each ligand molecule mentioned in Example 2 or its salt d , in 10 μmol / L TTR solution (1000 μL), dropwise add 100 μmol / L of the above-mentioned various ligand solutions at a rate of 1 μL / min, and use the built-in software to calculate the affinity binding equilibrium dissociation constant K d (Table 2).

[0079] Table 2 The affinity binding equilibrium dissociation constants of various ligand molecules and TTR

[0080]

[0081] As shown in Table 2, the equilibrium dissociation constants of affinity binding between various ligand molecules and TTR are close to 10 -8 mol / L, which is close to the ability of monoclonal antibodies to recognize a single epitope, indicating that the above-mentioned ligand molecules can specifically recognize and bind to TTR. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an ophthalmic preparation. The ophthalmic preparation comprises a compound, pharmaceutically acceptable salt or glucoside of the compound and transthyretin; and the compound is selected from one or more of diclofenac, vitamin A and luteolin. The present invention also provides a preparation method and an application of the ophthalmic preparation. The transthyretin and the compound in the ophthalmic preparation can be synergistically matched, so that when the ophthalmic preparation is used for treating eye diseases, the ophthalmic preparation can remarkably improve treatment effects on the eye diseases related to ocular angiogenesis and/or ocular retinal leakage, etc.

Description

technical field [0001] The invention belongs to the technical field of protein engineering, and specifically relates to an ophthalmic preparation containing transthyretin and a specific compound, a preparation method and application thereof. Background technique [0002] Diclofenac and its sodium salt: Diclofenac and its sodium salt are non-steroidal anti-inflammatory drugs, which have obvious analgesic, anti-inflammatory and antipyretic effects. Diclofenac sodium eye drops are used to treat uveitis, keratitis, scleritis, and inhibit the formation of corneal neovascularization; treat inflammatory reactions after intraocular surgery, laser lauteroplasty, or various eye injuries; inhibit cataracts Miotic reaction during surgery; pain relief and anti-inflammation after excimer laser keratectomy; treatment of allergic eye diseases such as vernal conjunctivitis and seasonal allergic conjunctivitis; prevention and treatment of cataract and intraocular lens postoperative inflammati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P27/02A61P9/10A61K31/196A61K31/07A61K31/352
CPCA61K38/1709A61K31/196A61K31/07A61K31/352A61P27/02A61P9/10A61K9/0048A61K2300/00
Inventor 辛瑜
Owner 易舟(上海)生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap